HOME >> BIOLOGY >> NEWS
International study findings link acne-like rash to effectiveness of new targeted cancer treatment

Geneva, Switzerland: Acne is not a condition that anyone would welcome under normal circumstances, but an international study of a new targeted cancer treatment cetuximab has shown that patients who developed an acne-like rash responded better to the treatment than those who did not.

Professor Eric Van Cutsem told a news briefing today (Thursday 30 September) at the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics that a trial, conducted in Belgium and the USA, had demonstrated that the more severe the rash the better the patients' tumours had responded to the treatment and the longer was their median survival.

Professor Van Cutsem, who is head of the Digestive Oncology Unit and Professor of Medicine at University Hospital Gasthuisberg in Leuven, said 346 patients with advanced colorectal cancer were treated in the study in Leuven and other Belgian and U.S. centres.

All the patients had metastatic cancer and had failed to respond to at least two prior chemotherapy regimens, although all still had a reasonable quality of life, either being fully active or at least still able to carry out light work.

Cetuximab, also known as Erbitux, is a new targeted treatment a monoclonal antibody designed to home in selectively on a protein called the epidermal growth factor (EGFR). EGFR is found on the surface of some cells and plays a role in regulating cell growth. Cetuximab interferes with the growth of cancer cells by binding to EGFR. It is approved by the Food and Drug Administration in the USA for use with the cancer drug irinotecan for colorectal cancer that has failed other treatments. It is also the first monoclonal antibody targeting EGFR to have gained marketing authorisation in Europe and is now being evaluated in first-line treatment of colorectal cancer, with promising results.

Professor Van Cutsem said that the acne-like rash was also a side effect of other EGFR inhibitors but it was not
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
30-Sep-2004


Page: 1 2

Related biology news :

1. USAID, Conservation International & Starbucks launch Conservation Coffee Alliance in Central America
2. ConocoPhillips & Conservation International launch Biodiversity Action Plan in Venezuela
3. A room with a view for the International Space Station: Completion of the cupola observation module
4. International symposium on nutritional genomics
5. First International Scientific Conference on Childhood Leukaemia
6. 1st International Conference on Cell Therapy for Cardiovascular Disease
7. International research conferences at the Villa Vigoni
8. Conservation International & SC Johnson invest in Ecuadors rainforest to offset climate impacts
9. STN International launches Derwent World Patents Index First View
10. Media invited to attend International Society For Heart & Lung Transplantation meeting April 21-24
11. International critical care doctors release first-ever guidelines for sepsis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ... of online age and identity verification solutions, announced today ... Identity Conference 2017, May 15 thru May 17, 2017, ... Building and International Trade Center. Identity ... globe and in today,s quickly evolving digital world, defining ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
Breaking Biology Technology:
Cached News: